期刊文献+

Ki-67和拓扑异构酶Ⅱα在喉鳞状细胞癌中的表达及意义 被引量:2

The expression of Ki-67、topoIIα in laryngeal squamous cell carcinoma
原文传递
导出
摘要 目的:检测喉鳞状细胞癌组织中Ki67、topoⅡα的表达,并分析其表达强度与喉鳞状细胞癌的组织学分级、临床分期及有无淋巴结转移的关系。方法:采用免疫组织化学法检测24例喉鳞状细胞癌及8例(对照组)声带息肉中Ki67、topoⅡα的表达。结果:喉鳞状细胞癌患者Ki67,topoⅡα的阳性率(43.86%,45.74%)明显高于对照组(5.66%,5.98%)(P<0.01),Ki67、topoⅡα的表达强度与癌组织的分化程度相关,topoⅡα/Ki67的比值与是否存在淋巴结转移差异有统计学意义(P<0.05)。结论:Ki67,topoⅡα的表达强度可判断癌组织分化程度,topoⅡα/Ki67可作为喉鳞状细胞癌患者预后的监测指标之一。 objective:To investigate the expression of ki-67 and topoⅡα in laryngeal squamous cell carcinoma, and the relationship between its intensity and the histological grade clinical stage and lymphoma metastasis.Method:The levels of ki-67 and topoⅡα in larynx were measured by immunohistochemical method.Result:The positive rate of ki-67 and topoⅡα in laryngeal squamous cell carcinoma were 43.86% and 45.74%,respectively,and that in the control group were 5.66% and 5.98%,respectively.And significant difference was found between the two groups(P<0.01).The intensity of ki-67 and topoⅡα expression correlated with histological grade. topoⅡα/ ki-67 has a relationship to lymphoma metastasis.Conclusion:The intensity of ki-67 and topoⅡα expression can evaluate the histological grade of carcinoma.topoⅡα/ ki-67 is an indicator of prognosis of Laryngeal Squamous Cell carcinoma.
出处 《临床耳鼻咽喉科杂志》 CAS CSCD 北大核心 2005年第9期396-398,共3页 Journal of Clinical Otorhinolaryngology
关键词 喉肿瘤 KI-67 topoⅡα Laryngeal neoplasms Ki-67 topoⅡα
  • 相关文献

参考文献6

  • 1Duchrow M,Gerdes J, Schluter C. The proliferation associated Ki-67 protein: definition in molecular terms.Cell Prolif, 1994,27: 235- 242.
  • 2Nakano T, Oka K. Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cerrical cancer. Cancer, 1993,72: 2401 - 2408.
  • 3Yabuki N,Sasano H,Kato K,et al. Immunohistochemical study of DNA topisomerasell in human gastric disorder. Am J Pathol,1996,149:997-1007.
  • 4Golusinski W, Oiofsson J, Szmeja Z, et al. A comprehensive analysis of selected diagnostic methods with respect to their usefulness in evaluating the biology of neoplastic cells in patients with laryngeal cancer. Eur Arch Otorhinolaryngol, 1999,256 : 306 - 311.
  • 5Schluter C,Duchrow M, Wohlemberg C, et al. The cell proliferation-associated antigen of Ki-67: a very large,ubiquitious nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Bio,1993,123:513-522.
  • 6Liu M, Lawson G, Delos M, et al. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Eur Arch Otorhinolaryngol, 2003,260: 28- 34.

同被引文献16

  • 1郭亚青,彭诗东.拓扑异构酶Ⅱ与头颈肿瘤化疗的研究进展[J].内蒙古医学院学报,2005,27(6):33-35. 被引量:1
  • 2[1]MacGrogan G,Rudolph P,Mascarel Ⅱ,et al.DNA topoisomerase Ⅱ alpha expression and the response toprimary chemotherapy in breast cancer[J].Br J Cancer,2003,89:666.
  • 3[2]Yabuki N,Sasano H,Kato K,et al.Immunohistochemical study of DNA topoisomerase Ⅱ in human gastric disorder[J].Am J Pathol,1996,149:997.
  • 4[4]Noraki W,Masura A,Takieo N,et al.Prognostic significence of Ki67 labeling index obtained by using MIB-1 monoclonalantibody in patients with superatentorial astrocytomas[J].Cancer,1996,77:373.
  • 5[5]Korshunov A,Shishkina L,Golanov A.DNA topoisomerase Ⅱ -alpha and cyclin A immunoexpression in meningiomas and its prognostic significance:an analysis of 263 cases[J].Arch Pathol Lab Med,2002,126:1079.
  • 6[6]Preusser M,Wolfsberger S,Czech T.Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome[J].Am J Clin Pathol,2005,124:543.
  • 7[7]Duchrow M,Gerdes J,Schluter C.The proliferation associated Ki67 protein:definition in molecular terms[J].Cell Prolif,1994,27:235.
  • 8[8]akano T,Oka K.Differential values of Ki-67 index and mitotic index of proliferating cell population.An assessment of cell cycle and prognosis in radiation therapy for cervical cancer[J].Cancer,1993,72:2401.
  • 9[9]Mckeever PE,Ross DA,Strawderman MS,et al.A comparison of the predictive power for survival in gliomas provided by MIB-1,bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters[J].J Neuropathol Exp Neurol,1997,56:798.
  • 10[10]Onda K,davis RR,Shibuya M,et al.Correlation between the bromodeoxyruidine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas[J].Cancer,1994,74:1921.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部